Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 8 pages · Chinese
Earlier from BeOne Medicines
- BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
- BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Announcement on Renewing Engagement of Audit Institution for 2025
- Announcement on the Equity Registration Date for the 1st Extraordinary General Meeting in 2025
- Notice on Convening the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2025
Later from BeOne Medicines
- BeiGene to Announce First Quarter 2025 Financial Results on May 7
- Announcement on Convening the 2024 Annual Performance Briefing
- 2024 Annual Report
- U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
- BeiGene Announces First Quarter 2025 Financial Results and Business Updates
Follow BeOne Medicines into a list and get an email when it puts out news.
Follow BeOne Medicines